UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Complement dysregulation is associated with severe COVID-19 illness

Haematologica (Roma), 2022-05, Vol.107 (5), p.1095

2022

Volltextzugriff (PDF)

Alternative pathway of cell death in Drosophila mediated by NF-κB transcription factor Relish

Proceedings of the National Academy of Sciences - PNAS, 2012-03, Vol.109 (10), p.E605-E612

2012

Volltextzugriff (PDF)

How to recognize and manage COVID-19-associated coagulopathy

Hematology, 2021-12, Vol.2021 (1), p.614-620

2021

Volltextzugriff (PDF)

SARS‐CoV‐2 infection results in upregulation of Plasminogen Activator Inhibitor‐1 and Neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severity

EJHaem, 2023-05, Vol.4 (2), p.324-338

2023

Volltextzugriff (PDF)

Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

Leukemia research reports, 2024-01, Vol.22, p.100469, Article 100469

2024

Volltextzugriff (PDF)

Pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Blood, 2022-06, Vol.139 (23), p.3361-3365

2022

Volltextzugriff (PDF)

Peri- and Postpartum Management of Patients With Factor XI Deficiency

Clinical and applied thrombosis/hemostasis, 2019, Vol.25, p.1076029619880262-1076029619880262

2019

Volltextzugriff (PDF)

Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management

Clinical immunology (Orlando, Fla.), 2023-12, Vol.257, p.109828-109828, Article 109828

2023

Volltextzugriff (PDF)

Medical consult: aHUS, TTP? How to distinguish and what to do

Hematology, 2023-12, Vol.2023 (1), p.745

2023

Volltextzugriff (PDF)

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

Blood, 2021-07, Vol.137 (26), p.3670-3673

2021

Volltextzugriff (PDF)

A 15‐year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism

American journal of hematology, 2022-02, Vol.97 (2), p.E59-E62

2022

Volltextzugriff (PDF)

Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition

Blood, 2023-07, Vol.142 (4), p.325-335

2023

Volltextzugriff (PDF)

A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism

Blood, 2023-06, Vol.141 (25), p.3109-3121

2023

Volltextzugriff (PDF)

Anti-PF4 antibodies associated with disease severity in COVID-19

Proceedings of the National Academy of Sciences - PNAS, 2022-11, Vol.119 (47), p.1-e2213361119

2022

Volltextzugriff (PDF)

Novel Functional Assay to Characterize Mutations in Alternative Pathway of Complement

Journal of clinical immunology, 2023-08, Vol.43 (6), p.1134-1136

2023

Volltextzugriff (PDF)

ADP: the missing link between thrombosis and hemolysis

Blood advances, 2023-10, Vol.7 (20), p.6364-6366

2023

Volltextzugriff (PDF)

Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings

Research and practice in thrombosis and haemostasis, 2024-05, Vol.8 (4), p.102416-102416, Article 102416

2024

Volltextzugriff (PDF)

Evaluating complement dysregulation in livedoid vasculopathy using a functional assay

Blood advances, 2023-11, Vol.7 (21), p.6604-6607

2023

Volltextzugriff (PDF)

Alternative pathway of cell death in Drosophila mediated by NF-κB transcription factor Relish

Proceedings of the National Academy of Sciences - PNAS, 2012-03, Vol.109 (10), p.3612-3613

2012

Volltextzugriff (PDF)

Alternative pathway of cell death in Drosophila mediated by NF-[kappa]B transcription factor Relish

Proceedings of the National Academy of Sciences - PNAS, 2012-03, Vol.109 (10), p.E605

2012

Volltextzugriff (PDF)

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

Blood, 2021, Vol.137 (26), p.3670-3673

2021

Volltextzugriff (PDF)

Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF

The Journal of biological chemistry, 2006-01, Vol.281 (2), p.951-961

2006

Volltextzugriff (PDF)

Analysis of shared heritability in common disorders of the brain

Science (American Association for the Advancement of Science), 2018-06, Vol.360 (6395), p.1313

2018

Volltextzugriff (PDF)

Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma

Clinical cancer research, 2006-05, Vol.12 (9), p.2676-2688

2006

Volltextzugriff (PDF)

P1.04-71 Tumor Burden Is Not Associated with Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S469-S469

2019

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)
Berichte
(1)

Sprache

Englisch
(27)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Complement dysregulation is associated with severe COVID-19 illness

Alternative pathway of cell death in Drosophila mediated by NF-κB transcription factor Relish

How to recognize and manage COVID-19-associated coagulopathy

SARS‐CoV‐2 infection results in upregulation of Plasminogen Activator Inhibitor‐1 and Neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severity

Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

Pegcetacoplan for paroxysmal nocturnal hemoglobinuria

Peri- and Postpartum Management of Patients With Factor XI Deficiency

Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management

Medical consult: aHUS, TTP? How to distinguish and what to do

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

A 15‐year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism

Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition

A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism

Anti-PF4 antibodies associated with disease severity in COVID-19

Novel Functional Assay to Characterize Mutations in Alternative Pathway of Complement

ADP: the missing link between thrombosis and hemolysis

Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings

Evaluating complement dysregulation in livedoid vasculopathy using a functional assay

Alternative pathway of cell death in Drosophila mediated by NF-κB transcription factor Relish

Alternative pathway of cell death in Drosophila mediated by NF-[kappa]B transcription factor Relish

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF

Analysis of shared heritability in common disorders of the brain

Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma

P1.04-71 Tumor Burden Is Not Associated with Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer

Suchergebnisse filtern